

Candidate SNPs in xenobiotic metabolism pathways involved in childhood acute lymphoblastic leukemia susceptibility

学位名	修士(公衆衛生学)
学位授与機関	聖路加国際大学
学位授与年度	2020
学位授与番号	32633公修専第077
URL	http://hdl.handle.net/10285/00016439

References

1. Buffler, P.A., et al., *Environmental and Genetic Risk Factors for Childhood Leukemia: Appraising the Evidence*. *Cancer Investigation*, 2009. **23**(1): p. 60-75.
2. Filippini, T., et al., *Association between Outdoor Air Pollution and Childhood Leukemia: A Systematic Review and Dose-Response Meta-Analysis*. *Environ Health Perspect*, 2019. **127**(4): p. 46002.
3. Gong, Z.H., et al., *A Meta-analysis of Traffic-related Air Pollution and Risk of Childhood Leukemia*. *J Pediatr Hematol Oncol*, 2019. **41**(4): p. 267-274.
4. Chunxia, D., et al., *Tobacco smoke exposure and the risk of childhood acute lymphoblastic leukemia and acute myeloid leukemia: A meta-analysis*. *Medicine (Baltimore)*, 2019. **98**(28): p. e16454.
5. Lu, Y., et al., *Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia*. *Br J Cancer*, 2014. **110**(6): p. 1673-80.
6. Urayama, K.Y., et al., *Regional evaluation of childhood acute lymphoblastic leukemia genetic susceptibility loci among Japanese*. *Sci Rep*, 2018. **8**(1): p. 789.
7. Enciso-Mora, V., et al., *Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia*. *Leukemia*, 2012. **26**(10): p. 2212-5.
8. Hsu, L.I., et al., *Pathway Analysis of Genome-wide Association Study in Childhood Leukemia among Hispanics*. *Cancer Epidemiol Biomarkers Prev*, 2016. **25**(5): p. 815-22.
9. Urayama, K.Y., et al., *Current evidence for an inherited genetic basis of childhood acute lymphoblastic leukemia*. *Int J Hematol*, 2013. **97**(1): p. 3-19.
10. Muro, S., et al., *Relationship Among Chlamydia and Mycoplasma Pneumoniae Seropositivity, IKZF1 Genotype and Chronic Obstructive Pulmonary Disease in A General Japanese Population: The Nagahama Study*. *Medicine (Baltimore)*, 2016. **95**(15): p. e3371.
11. Inoue, M., et al., *Epidemiology of pancreatic cancer in Japan: a nested case-control study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC)*. *Int J Epidemiol*, 2003. **32**(2): p. 257-62.
12. Li, Y., et al., *Genotype imputation*. *Annu Rev Genomics Hum Genet*, 2009. **10**: p. 387-406.
13. O'Connell, J., et al., *Haplotype estimation for biobank-scale data sets*. *Nat Genet*, 2016. **48**(7): p. 817-20.
14. Das, S., et al., *Next-generation genotype imputation service and methods*. *Nat Genet*, 2016. **48**(10): p. 1284-1287.
15. Auton, A., et al., *A global reference for human genetic variation*. *Nature*, 2015. **526**(7571): p. 68-74.
16. Purcell, S., et al., *PLINK: a tool set for whole-genome association and population-based linkage analyses*. *Am J Hum Genet*, 2007. **81**(3): p. 559-75.
17. Pruim, R.J., et al., *LocusZoom: regional visualization of genome-wide association scan results*. *Bioinformatics*, 2010. **26**(18): p. 2336-7.
18. Machiela, M.J. and S.J. Chanock, *LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants*. *Bioinformatics*, 2015. **31**(21): p. 3555-7.
19. Silveira Vda, S., et al., *Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children*. *Environ Mol Mutagen*, 2010. **51**(1): p. 48-56.
20. Tumer, T.B., G. Sahin, and E. Arinç, *Association between polymorphisms of EPHX1 and XRCC1 genes and the risk of childhood acute lymphoblastic leukemia*. *Arch Toxicol*, 2012. **86**(3): p. 431-9.
21. Brisson, G.D., L.R. Alves, and M.S. Pombo-de-Oliveira, *Genetic susceptibility in childhood acute leukaemias: a systematic review*. *Ecancermedalscience*, 2015. **9**: p. 539.

22. Daci, A., et al., *Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients*. PLoS One, 2015. **10**(11): p. e0142408.
23. Zhao, G.X., et al., *Association between EPHX1 polymorphisms and carbamazepine metabolism in epilepsy: a meta-analysis*. Int J Clin Pharm, 2019. **41**(6): p. 1414-1428.
24. Xu, X., et al., *EPHX1 rs2234922 polymorphism and lung cancer susceptibility in Asian populations: a meta-analysis*. J Thorac Dis, 2015. **7**(7): p. 1125-9.
25. Chen, Z., et al., *Chronic effects of air pollution on respiratory health in Southern California children: findings from the Southern California Children's Health Study*. J Thorac Dis, 2015. **7**(1): p. 46-58.
26. Hassett, C., et al., *Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants*. Hum Mol Genet, 1994. **3**(3): p. 421-8.
27. Kim, S., et al., *Genetic polymorphisms and benzene metabolism in humans exposed to a wide range of air concentrations*. Pharmacogenet Genomics, 2007. **17**(10): p. 789-801.
28. Murray, G.I., et al., *Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1*. Annu Rev Pharmacol Toxicol, 2001. **41**: p. 297-316.
29. Alsubait, A., et al., *CYP1B1 gene: Implications in glaucoma and cancer*. J Cancer, 2020. **11**(16): p. 4652-4661.
30. Bart, A.G., et al., *Structure of an ancestral mammalian family 1B1 cytochrome P450 with increased thermostability*. J Biol Chem, 2020. **295**(17): p. 5640-5653.
31. Falero-Perez, J., et al., *CYP1B1: A key regulator of redox homeostasis*. Trends Cell Mol Biol, 2018. **13**: p. 27-45.
32. Morvan, V.L., et al., *Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma*. Br J Cancer, 2020. **123**(5): p. 772-784.
33. Shimada, T., et al., *Catalytic properties of polymorphic human cytochrome P450 1B1 variants*. Carcinogenesis, 1999. **20**(8): p. 1607-13.
34. Beranek, M., et al., *Genetic polymorphisms in biotransformation enzymes for benzo[a]pyrene and related levels of benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in Goeckerman therapy*. Toxicol Lett, 2016. **255**: p. 47-51.
35. Sun, P., et al., *[Genetic polymorphisms of MPO, NQO1, GSTP1, UGT1A6 associated with susceptibility of chronic benzene poisoning]*. Wei Sheng Yan Jiu, 2007. **36**(1): p. 11-5.
36. Mei, S., et al., *Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy*. Seizure, 2017. **51**: p. 22-26.
37. Feng, W., et al., *Effects of UGT1A6 and GABRA1 on Standardized Valproic Acid Plasma Concentrations and Treatment Effect in Children With Epilepsy in China*. Ther Drug Monit, 2016. **38**(6): p. 738-743.
38. García-Closas, M., et al., *NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses*. Lancet, 2005. **366**(9486): p. 649-59.
39. Zhu, X., et al., *Association between NAT2 polymorphisms and acute leukemia risk: A meta-analysis*. Medicine (Baltimore), 2019. **98**(12): p. e14942.
40. Zanrosso, C.W., et al., *N-acetyltransferase 2 polymorphisms and susceptibility to infant leukemia with maternal exposure to dipyrone during pregnancy*. Cancer Epidemiol Biomarkers Prev, 2010. **19**(12): p. 3037-43.
41. García-Martín, E., et al., *Genetic determinants of metamizole metabolism modify the risk of developing anaphylaxis*. Pharmacogenet Genomics, 2015. **25**(9): p. 462-4.
42. Risch, A., et al., *Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer*. Hum Mol Genet, 1995. **4**(2): p. 231-6.
43. Chen, J., et al., *A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer*. Cancer Res, 1998. **58**(15): p. 3307-11.

1. Buffler, P.A., et al., *Environmental and Genetic Risk Factors for Childhood Leukemia: Appraising the Evidence*. Cancer Investigation, 2009. **23**(1): p. 60-75.
2. Filippini, T., et al., *Association between Outdoor Air Pollution and Childhood Leukemia: A Systematic Review and Dose-Response Meta-Analysis*. Environ Health Perspect, 2019. **127**(4): p. 46002.
3. Gong, Z.H., et al., *A Meta-analysis of Traffic-related Air Pollution and Risk of Childhood Leukemia*. J Pediatr Hematol Oncol, 2019. **41**(4): p. 267-274.
4. Chunxia, D., et al., *Tobacco smoke exposure and the risk of childhood acute lymphoblastic leukemia and acute myeloid leukemia: A meta-analysis*. Medicine (Baltimore), 2019. **98**(28): p. e16454.
5. Lu, Y., et al., *Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia*. Br J Cancer, 2014. **110**(6): p. 1673-80.
6. Urayama, K.Y., et al., *Regional evaluation of childhood acute lymphoblastic leukemia genetic susceptibility loci among Japanese*. Sci Rep, 2018. **8**(1): p. 789.
7. Enciso-Mora, V., et al., *Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia*. Leukemia, 2012. **26**(10): p. 2212-5.
8. Hsu, L.I., et al., *Pathway Analysis of Genome-wide Association Study in Childhood Leukemia among Hispanics*. Cancer Epidemiol Biomarkers Prev, 2016. **25**(5): p. 815-22.
9. Urayama, K.Y., et al., *Current evidence for an inherited genetic basis of childhood acute lymphoblastic leukemia*. Int J Hematol, 2013. **97**(1): p. 3-19.
10. Muro, S., et al., *Relationship Among Chlamydia and Mycoplasma Pneumoniae Seropositivity, IKZF1 Genotype and Chronic Obstructive Pulmonary Disease in A General Japanese Population: The Nagahama Study*. Medicine (Baltimore), 2016. **95**(15): p. e3371.
11. Inoue, M., et al., *Epidemiology of pancreatic cancer in Japan: a nested case-control study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC)*. Int J Epidemiol, 2003. **32**(2): p. 257-62.
12. Li, Y., et al., *Genotype imputation*. Annu Rev Genomics Hum Genet, 2009. **10**: p. 387-406.
13. O'Connell, J., et al., *Haplotype estimation for biobank-scale data sets*. Nat Genet, 2016. **48**(7): p. 817-20.
14. Das, S., et al., *Next-generation genotype imputation service and methods*. Nat Genet, 2016. **48**(10): p. 1284-1287.
15. Auton, A., et al., *A global reference for human genetic variation*. Nature, 2015. **526**(7571): p. 68-74.
16. Purcell, S., et al., *PLINK: a tool set for whole-genome association and population-based linkage analyses*. Am J Hum Genet, 2007. **81**(3): p. 559-75.
17. Pruim, R.J., et al., *LocusZoom: regional visualization of genome-wide association scan results*. Bioinformatics, 2010. **26**(18): p. 2336-7.
18. Machiela, M.J. and S.J. Chanock, *LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants*. Bioinformatics, 2015. **31**(21): p. 3555-7.
19. Silveira Vda, S., et al., *Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children*. Environ Mol Mutagen, 2010. **51**(1): p. 48-56.
20. Tumer, T.B., G. Sahin, and E. Arinç, *Association between polymorphisms of EPHX1 and XRCC1 genes and the risk of childhood acute lymphoblastic leukemia*. Arch Toxicol, 2012. **86**(3): p. 431-9.
21. Brisson, G.D., L.R. Alves, and M.S. Pombo-de-Oliveira, *Genetic susceptibility in childhood acute leukaemias: a systematic review*. Ecancermedicallscience, 2015. **9**: p. 539.
22. Daci, A., et al., *Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients*. PLoS One, 2015. **10**(11): p. e0142408.

23. Zhao, G.X., et al., *Association between EPHX1 polymorphisms and carbamazepine metabolism in epilepsy: a meta-analysis*. *Int J Clin Pharm*, 2019. **41**(6): p. 1414-1428.
24. Xu, X., et al., *EPHX1 rs2234922 polymorphism and lung cancer susceptibility in Asian populations: a meta-analysis*. *J Thorac Dis*, 2015. **7**(7): p. 1125-9.
25. Chen, Z., et al., *Chronic effects of air pollution on respiratory health in Southern California children: findings from the Southern California Children's Health Study*. *J Thorac Dis*, 2015. **7**(1): p. 46-58.
26. Hassett, C., et al., *Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants*. *Hum Mol Genet*, 1994. **3**(3): p. 421-8.
27. Kim, S., et al., *Genetic polymorphisms and benzene metabolism in humans exposed to a wide range of air concentrations*. *Pharmacogenet Genomics*, 2007. **17**(10): p. 789-801.
28. Murray, G.I., et al., *Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1*. *Annu Rev Pharmacol Toxicol*, 2001. **41**: p. 297-316.
29. Alsubait, A., et al., *CYP1B1 gene: Implications in glaucoma and cancer*. *J Cancer*, 2020. **11**(16): p. 4652-4661.
30. Bart, A.G., et al., *Structure of an ancestral mammalian family 1B1 cytochrome P450 with increased thermostability*. *J Biol Chem*, 2020. **295**(17): p. 5640-5653.
31. Falero-Perez, J., et al., *CYP1B1: A key regulator of redox homeostasis*. *Trends Cell Mol Biol*, 2018. **13**: p. 27-45.
32. Morvan, V.L., et al., *Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma*. *Br J Cancer*, 2020. **123**(5): p. 772-784.
33. Shimada, T., et al., *Catalytic properties of polymorphic human cytochrome P450 1B1 variants*. *Carcinogenesis*, 1999. **20**(8): p. 1607-13.
34. Beranek, M., et al., *Genetic polymorphisms in biotransformation enzymes for benzo[a]pyrene and related levels of benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in Goeckerman therapy*. *Toxicol Lett*, 2016. **255**: p. 47-51.
35. Sun, P., et al., *[Genetic polymorphisms of MPO, NQO1, GSTP1, UGT1A6 associated with susceptibility of chronic benzene poisoning]*. *Wei Sheng Yan Jiu*, 2007. **36**(1): p. 11-5.
36. Mei, S., et al., *Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy*. *Seizure*, 2017. **51**: p. 22-26.
37. Feng, W., et al., *Effects of UGT1A6 and GABRA1 on Standardized Valproic Acid Plasma Concentrations and Treatment Effect in Children With Epilepsy in China*. *Ther Drug Monit*, 2016. **38**(6): p. 738-743.
38. García-Closas, M., et al., *NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses*. *Lancet*, 2005. **366**(9486): p. 649-59.
39. Zhu, X., et al., *Association between NAT2 polymorphisms and acute leukemia risk: A meta-analysis*. *Medicine (Baltimore)*, 2019. **98**(12): p. e14942.
40. Zanrosso, C.W., et al., *N-acetyltransferase 2 polymorphisms and susceptibility to infant leukemia with maternal exposure to dipyrone during pregnancy*. *Cancer Epidemiol Biomarkers Prev*, 2010. **19**(12): p. 3037-43.
41. García-Martín, E., et al., *Genetic determinants of metamizole metabolism modify the risk of developing anaphylaxis*. *Pharmacogenet Genomics*, 2015. **25**(9): p. 462-4.
42. Risch, A., et al., *Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer*. *Hum Mol Genet*, 1995. **4**(2): p. 231-6.
43. Chen, J., et al., *A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer*. *Cancer Res*, 1998. **58**(15): p. 3307-11.